Literature DB >> 11188981

The biochemistry of botulinum toxin type B.

P Setler1.   

Abstract

Botulinum toxin type B (BTX-B) is a member of a family of neurotoxins produced by the anaerobic bacteria Clostridium botulinum. BTXs specifically inhibit acetylcholine release at the neuromuscular junction and cause muscle paralysis in humans. The mechanism of action of BTXs involves inactivation of the neural exocytotic pathway by proteolytic cleavage of components of the exocytotic apparatus. Purified BTXs have been used clinically to treat disorders of muscle contraction, such as spasticity and dystonia. BTXs are purified as high molecular weight complexes that contain additional bacterial proteins which function to protect the toxin molecule. BTX complexes are stable in solution only at acidic pH. A new method was developed to purify intact BTX-B complexes. The resulting liquid formulation of high specific activity BTX-B (Elan's BTX-B evaluated as NeuroBloc) is buffered at pH 5.6 and demonstrates long-term stability at 2 to 25 degrees C.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11188981

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

1.  Purification of fully activated Clostridium botulinum serotype B toxin for treatment of patients with dystonia.

Authors:  Hideyuki Arimitsu; Kaoru Inoue; Yoshihiko Sakaguchi; Jaechul Lee; Yukako Fujinaga; Toshihiro Watanabe; Tohru Ohyama; Robert Hirst; Keiji Oguma
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

2.  [Pharmacology of botulinum toxin drugs].

Authors:  D Dressler
Journal:  HNO       Date:  2012-06       Impact factor: 1.284

Review 3.  Use of botulinum toxin in the neurology clinic.

Authors:  Erle C H Lim; Raymond C S Seet
Journal:  Nat Rev Neurol       Date:  2010-10-12       Impact factor: 42.937

Review 4.  [Pharmacological aspects of therapeutic botulinum toxin preparations].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2006-08       Impact factor: 1.214

Review 5.  Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal.

Authors:  A Ferrari; M Manca; V Tugnoli; L Alberto
Journal:  Funct Neurol       Date:  2018 Jan/Mar

6.  Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.

Authors:  Dirk Dressler; Hans Bigalke
Journal:  J Neurol       Date:  2005-03-11       Impact factor: 4.849

7.  Evaluation of efficacy and safety of botulinum toxin type A injection in patients requiring temporary tarsorrhaphy to improve corneal epithelial defects.

Authors:  Abolfazl Kasaee; Mohammad Reza Musavi; Syed Ziaeddin Tabatabaie; Mohammad Nasser Hashemian; Shahrzad Mohebbi; Alireza Khodabandeh; Mohammad Taher Rajabi
Journal:  Int J Ophthalmol       Date:  2010-09-18       Impact factor: 1.779

Review 8.  Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.

Authors:  David P Figgitt; Stuart Noble
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Botulinum toxin type A in the treatment of patients with cervical dystonia.

Authors:  Allison Brashear
Journal:  Biologics       Date:  2009-07-13

Review 10.  Immunogenicity of botulinum toxins.

Authors:  Markus Naumann; Lee Ming Boo; Alan H Ackerman; Conor J Gallagher
Journal:  J Neural Transm (Vienna)       Date:  2012-09-25       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.